Insulin increases shedding of syndecan-1 in the serum of patients with type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 86, Issue 2, 2009, Pages 83-88

  Wang, Jing bo ^a   Guan, Juan ^a   Shen, Jing ^a   Zhou, Li ^a   Zhang, Yan jun ^b   Si, Yan fang ^a   Yang, Li ^c   Jian, Xiao hong ^a   Sheng, Yu ^a  

^a 309TH HOSPITAL OF PLA   (China)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c Jinan Normal School   (China)

Author keywords

Diabetes; Insulin; Serum; Syndecan 1

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; SYNDECAN 1;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; MALE; MIDDLE AGED; REFERENCE VALUES; SYNDECAN-1; TRIGLYCERIDES;

EID: 70349971758     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.08.002     Document Type: Article

References (37)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Alberti K.G. Treating type 2 diabetes-today's targets, tomorrow's goals. Diabetes Obes. Metab. 3 Suppl 1 (2001) 3-10
3. Seidell J.C. Obesity, insulin resistance and diabetes-a worldwide epidemic. Br. J. Nutr. 83 Suppl 1 (2000) S5-8
4. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21 (1998) 518-524
5. Stehouwer C.D., Lambert J., Donker A.J., and van Hinsbergh V.W. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 34 (1997) 55-68
6. Stehouwer C.D., Gall M.A., Twisk J.W., Knudsen E., Emeis J.J., and Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
7. Omi H., Okayama N., Shimizu M., Okouchi M., Ito S., Fukutomi T., et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J. Diabetes Complicat. 16 (2002) 201-208
8. Gomez J.M., Vila R., Catalina P., Soler J., Badimon L., and Sahun M. The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives. Glycoconj. J. 25 (2008) 573-579
9. Bernfield M., Kokenyesi R., Kato M., Hinkes M.T., Spring J., Gallo R.L., et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8 (1992) 365-393
10. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68 (1999) 729-777
11. Gotte M. Syndecans in inflammation. Faseb J. 17 (2003) 575-591
12. Alexopoulou A.N., Multhaupt H.A., and Couchman J.R. Syndecans in wound healing, inflammation and vascular biology. Int. J. Biochem. Cell Biol. 39 (2007) 505-528
13. Gotte M., Joussen A.M., Klein C., Andre P., Wagner D.D., Hinkes M.T., et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1135-1141
14. Reizes O., Goldberger O., Smith A.C., Xu Z., Bernfield M., and Bickel P.E. Insulin promotes shedding of syndecan ectodomains from 3T3-L1 adipocytes: a proposed mechanism for stabilization of extracellular lipoprotein lipase. Biochemistry 45 (2006) 5703-5711
15. Meigs J.B., Hu F.B., Rifai N., and Manson J.E. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. Jama 291 (2004) 1978-1986
16. Joussen A.M., Murata T., Tsujikawa A., Kirchhof B., Bursell S.E., and Adamis A.P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 158 (2001) 147-152
17. Miyamoto K., Khosrof S., Bursell S.E., Rohan R., Murata T., Clermont A.C., et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10836-10841
18. Rosales C., and Juliano R.L. Signal transduction by cell adhesion receptors in leukocytes. J. Leukoc. Biol. 57 (1995) 189-198
19. Alba-Loureiro T.C., Munhoz C.D., Martins J.O., Cerchiaro G.A., Scavone C., Curi R., et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz. J. Med. Biol. Res. 40 (2007) 1037-1044
20. Rosen S.D. Ligands for l-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 22 (2004) 129-156
21. Mayadas T.N., and Cullere X. Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol. 26 (2005) 388-395
22. Watchorn T.M., Waddell I., and Ross J.A. Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am. J. Physiol. Endocrinol. Metab. 282 (2002) E763-769
23. Elenius K., Vainio S., Laato M., Salmivirta M., Thesleff I., and Jalkanen M. Induced expression of syndecan in healing wounds. J. Cell Biol. 114 (1991) 585-595
24. Cizmeci S.G., and Carey D.J. Thrombin stimulates syndecan-1 promotor activity and expression of a form of syndecan-1 that binds antithrombin III in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2609-2616
25. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., and Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J. Cell Biol. 148 (2000) 811-824
26. Subramanian S.V., Fitzgerald M.L., and Bernfield M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J. Biol. Chem. 272 (1997) 14713-14720
27. Park P.W., Pier G.B., Preston M.J., Goldberger O., Fitzgerald M.L., and Bernfield M. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J. Biol. Chem. 275 (2000) 3057-3064
28. Wang J.B., Tian C.W., Guo C.M., Du H.J., Liu H.L., Zhang Y.J., et al. Increased levels of soluble syndecan-1 in the subretinal fluid and the vitreous of eyes with rhegmatogenous retinal detachment. Curr. Eye Res. 33 (2008) 101-107
29. Kim C.W., Goldberger O.A., Gallo R.L., and Bernfield M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol. Biol. Cell 5 (1994) 797-805
30. Woods A. Syndecans: transmembrane modulators of adhesion and matrix assembly. J. Clin. Invest. 107 (2001) 935-941
31. Joensuu H., Anttonen A., Eriksson M., Makitaro R., Alfthan H., Kinnula V., et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 62 (2002) 5210-5217
32. Leivonen M., Lundin J., Nordling S., von Boguslawski K., and Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 67 (2004) 11-18
33. Seidel C., Sundan A., Hjorth M., Turesson I., Dahl I.M., Abildgaard N., et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95 (2000) 388-392
34. Anttonen A., Leppa S., Ruotsalainen T., Alfthan H., Mattson K., and Joensuu H. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 41 (2003) 171-177
35. Aljada A., Saadeh R., Assian E., Ghanim H., and Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J. Clin. Endocrinol. Metab. 85 (2000) 2572-2575
36. Aljada A., Ghanim H., Saadeh R., and Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J. Clin. Endocrinol. Metab. 86 (2001) 450-453
37. Dandona P., Aljada A., Mohanty P., Ghanim H., Hamouda W., Assian E., et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?. J. Clin. Endocrinol. Metab. 86 (2001) 3257-3265